Axon Enterprise, Inc $AXON Shares Purchased by D.A. Davidson & CO.

D.A. Davidson & CO. increased its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 24.8% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 10,186 shares of the biotechnology company’s stock after purchasing an additional 2,023 shares during the period. D.A. Davidson & CO.’s holdings in Axon Enterprise were worth $4,326,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Axon Enterprise by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock valued at $5,319,928,000 after purchasing an additional 53,060 shares during the period. Geode Capital Management LLC boosted its position in shares of Axon Enterprise by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock worth $1,265,657,000 after buying an additional 35,544 shares during the period. Baillie Gifford & Co. boosted its position in shares of Axon Enterprise by 1,198.7% during the fourth quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock worth $932,869,000 after buying an additional 1,516,099 shares during the period. Sands Capital Management LLC grew its stake in shares of Axon Enterprise by 11.6% in the fourth quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock valued at $914,047,000 after buying an additional 167,095 shares in the last quarter. Finally, Wellington Management Group LLP grew its stake in shares of Axon Enterprise by 326.9% in the fourth quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock valued at $874,463,000 after buying an additional 1,179,038 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Insider Buying and Selling

In other Axon Enterprise news, President Joshua Isner sold 13,000 shares of the stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $488.45, for a total value of $6,349,850.00. Following the sale, the president owned 169,125 shares of the company’s stock, valued at $82,609,106.25. This trade represents a 7.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Caitlin Elizabeth Kalinowski sold 564 shares of Axon Enterprise stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $478.97, for a total value of $270,139.08. Following the completion of the transaction, the director owned 3,632 shares of the company’s stock, valued at $1,739,619.04. The trade was a 13.44% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 58,989 shares of company stock worth $30,527,983 over the last ninety days. Company insiders own 4.20% of the company’s stock.

Axon Enterprise Stock Down 5.8%

Axon Enterprise stock opened at $510.28 on Friday. The firm has a market capitalization of $41.13 billion, a P/E ratio of 204.93, a P/E/G ratio of 10.41 and a beta of 1.38. The company has a current ratio of 2.27, a quick ratio of 1.93 and a debt-to-equity ratio of 0.49. Axon Enterprise, Inc has a twelve month low of $339.01 and a twelve month high of $885.91. The stock’s fifty day simple moving average is $471.67 and its 200-day simple moving average is $481.88.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The firm had revenue of $807.35 million during the quarter, compared to analyst estimates of $778.90 million. During the same period last year, the business posted $1.47 earnings per share. Axon Enterprise’s revenue was up 33.7% compared to the same quarter last year. As a group, equities analysts expect that Axon Enterprise, Inc will post 1.63 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AXON has been the topic of several research reports. Morgan Stanley set a $600.00 target price on Axon Enterprise in a research note on Thursday, May 7th. Weiss Ratings raised Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. TD Cowen cut their price target on shares of Axon Enterprise from $950.00 to $825.00 and set a “buy” rating on the stock in a research note on Wednesday, April 8th. Citizens Jmp reissued a “market outperform” rating and set a $700.00 price target on shares of Axon Enterprise in a research report on Thursday, June 25th. Finally, Piper Sandler increased their price target on shares of Axon Enterprise from $674.00 to $724.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Fifteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Axon Enterprise currently has an average rating of “Moderate Buy” and an average price target of $725.25.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.